Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Urogen Pharma Ltd
(NQ:
URGN
)
13.24
+0.39 (+3.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Urogen Pharma Ltd
< Previous
1
2
3
4
Next >
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 11, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 28, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
September 12, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Upcoming 2022 Conferences
September 07, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 11, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 27, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
May 18, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 16, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 13, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
March 29, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
March 21, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
February 28, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
February 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
February 03, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Conferences
January 05, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
December 21, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 15, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Upcoming 2021 Conferences
November 11, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
November 10, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
November 01, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
October 05, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
September 13, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021
From
UroGen Pharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.